This approach in nuclear medicine combines the precision of targeted therapy with the potency of radiation. Specifically, it involves molecules designed to bind strongly and irreversibly (covalently) to specific receptors or proteins found predominantly on cancer cells. These molecules are linked to radioactive isotopes, effectively delivering a highly localized radiation dose directly to the tumor while minimizing damage to surrounding healthy tissues. This precision targeting is achieved through the specific binding properties of the molecule (ligand) to its target, analogous to a lock and key mechanism.
Delivering radiation directly to cancer cells offers significant advantages over traditional external beam radiation therapy or systemic chemotherapy, particularly in cases where tumors are difficult to access surgically or have metastasized. By minimizing off-target effects, this method can potentially reduce side effects and improve patient outcomes. The development of more effective and specific targeting molecules has been a driving force in advancing this field, building upon earlier forms of radionuclide therapy that lacked this level of precision.
